



AGENDA ITEM

2.1.4

POPULATION HEALTH & PARTNERSHIPS COMMITTEE

**CWM TAF MORGANNWG UNIVERSITY HEALTH BOARD ENDORSEMENT
OF THE CANCER RESEARCH STRATEGY FOR WALES**

Date of meeting	26th July 2022
FOI Status	Open/Public
If closed please indicate reason	Choose an item.
Prepared by	Prof John Geen
Presented by	Prof Kelechi Nnoaham
Approving Executive Sponsor	Executive Director of Public Health
Report purpose	ENDORSE FOR COMMITTEE APPROVAL

Engagement (internal/external) undertaken to date (including receipt/consideration at Committee/group)

Committee/Group/Individuals	Date	Outcome
Executive Leadership Group	18/7/2022	SUPPORTED

ACRONYMS

CTMUHB	Cwm Taf University Health Board
R&D	Research and Development

1. SITUATION/BACKGROUND

- 1.1 Cancer research in Wales covers the whole range of specialist fields from population behaviour, prevention, laboratory based research diagnostics, through to different therapeutic strategies.

- 1.2 The research activity is undertaken across different academic and clinical organisations, with support from the third sector and industry. The Cancer Research Strategy for Wales has been co-produced with input from the NHS, Academia, Public, third sector and an expert panel. The Cancer Research Strategy for Wales has been shared with the NHS R&D leadership across Wales throughout its development, with a final review, which received support in March 2022.
- 1.3 The Strategy sets the key research themes that will build on the current recognised areas of expertise and be further developed in Wales, helping inform where resources should be focussed to help increase cancer related research activity, in areas of strength and those requiring development.
- 1.4 The strategy provides a mechanism for setting the research priorities and facilitating the co-ordination of research between all stakeholders, including CTMUHB. In turn this will provide easy and equitable access for patients to participate in research across Wales and also help develop research leaders, welsh lead research and principal investigators in the field of cancer.
- 1.5 Increasing support for research delivery at cancer outreach services such as those provided at Cwm Taf Morgannwg, to ensure equity of patient access will also form part of the strategy.

2. SPECIFIC MATTERS FOR CONSIDERATION BY THIS MEETING (ASSESSMENT)

- 2.1 The Committee is asked to **ENDORSE** their support for the Cancer Research Strategy for Wales that was supported by the Executive Leadership Group on the 18 July 2022

3. KEY RISKS/MATTERS FOR ESCALATION TO BOARD/COMMITTEE

- 3.1 No risks anticipated.

4. IMPACT ASSESSMENT

Quality/Safety/Patient Experience implications	There are no specific quality and safety implications related to the activity outlined in this report.
---	--



Related Health and Care standard(s)	Governance, Leadership and Accountability
	If more than one Healthcare Standard applies please list below:
Equality Impact Assessment (EIA) completed - Please note EIAs are required for <u>all</u> new, changed or withdrawn policies and services.	Choose an item. If yes, please provide a hyperlink to the location of the completed EIA or who it would be available from in the box below. If no, please provide reasons why an EIA was not considered to be required in the box below.
	An EIA has not been completed because the document being endorsed is not an internal policy or service.
Legal implications / impact	There are no specific legal implications related to the activity outlined in this report.
Resource (Capital/Revenue £/Workforce) implications / Impact	There is no direct impact on resources as a result of the activity outlined in this report.
Link to Strategic Goals	Improving Care

5. RECOMMENDATION

- 5.1 The Committee is asked to **ENDORSE** their support for the Cancer Research Strategy for Wales that was supported by the Executive Leadership Group on the 18 July 2022.